Regulation of tyrosine hydroxylase by GPE

Details Regulation of tyrosine hydroxylase by GPE Regulation of tyrosine hydroxylase by GPE

2005-08-23

2005-08-23

Russel, Jeffrey Edwin (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

06933282

ABSTRACT:
Embodiments of this invention include methods for increasing the amount of the enzyme tyrosine hydroxylase (TH) in the central nervous system (CNS) of mammals in need of an increase in TH. Methods include the use of the tripeptide, gly-pro-glu (GPE) to increase TH in the CNS. GPE can increase the amount of TH and/or decrease the loss of TH in conditions characterized by a loss of dopamine, such as Parkinson's disease and CNS injury. GPE may act to increase the expression of TH or by inhibiting a decrease in TH expression within the CNS or by inhibiting the loss of TH-containing neurons within the CNS. By increasing the amounts of TH in the CNS, GPE can increase the amount of the neurotransmitter, dopamine, in areas of the CNS responsible for adverse symptoms of neural injury or disease.

REFERENCES:
patent: 5714460 (1998-02-01), Gluckman et al.
patent: 6187906 (2001-02-01), Gluckman et al.
patent: 6294585 (2001-09-01), Brown
patent: 6617311 (2003-09-01), Gluckman et al.
patent: 6682753 (2004-01-01), Alexi
patent: 6780848 (2004-08-01), Gluckman et al.
patent: 0 366 638 (1990-05-01), None
patent: WO 95/17204 (1995-06-01), None
patent: WO 98/14202 (1998-04-01), None
Sara, Vicki R., et. al., “The Biological Role of Truncated Insulin-like Growth Factor-1 and the Tripeptide GPE in the Central Nervous System”, Annals of the New York Academy of Sciences, 692, 1993, 183-191.
Sara, Vicki R., et. al., “Identification of Gly-Pro-Glu (GPE), the Aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide”, Biochemical and Biophysical Research Communications, vol. 165, No. 2, Dec. 15, 1989, 766-771.
Saura, J., et. al., “Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro”, NeuroReport, vol. 10, No. 1, Jan. 1999, 161-164.
Nilsson-Hakansson, Lena et. al., “Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain”, NeuroReport, vol. 4, No. 9, Aug. 1993, (Sep. Issue), 1111-1114.
Ludecke et al., “Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by point mutation (L205P) in the tyrosine hydrolyse gene”, Hum. Gen. 102:644-646 (1998).
Danks et al., “Tetrahydrobiopterin treatment of variant form of phenylketonuria”, Lancet 2:1043, 1975.
Ludecke et al., A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome , Hum. Gen. 93:123 (1995).
Mallet, “Tyrosine hydroxylase from cloning to neuropsychiatric disorders”, Brain Research Bulletin 50(5,6):381-382 (1992).
Guan et al., “N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats”, Brain research Mar. 24, 2000 859(2), 286-92.

Affiliated with

Also associated with

Rating

Regulation of tyrosine hydroxylase by GPE does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Regulation of tyrosine hydroxylase by GPE, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulation of tyrosine hydroxylase by GPE will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3475142